<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870986</url>
  </required_header>
  <id_info>
    <org_study_id>B5381001</org_study_id>
    <secondary_id>REFLECTIONS B538-01</secondary_id>
    <nct_id>NCT01870986</nct_id>
  </id_info>
  <brief_title>Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)</brief_title>
  <official_title>Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This healthy volunteers study will evaluate 210 subjects who will receive a single
      sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European
      Union). This study will involve sampling and pharmacokinetics evaluation of drug levels
      following administration of PF-06410293 and the licensed adalimumab products.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>Day 1 - Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Time Point with Quantifiable Concentration (AUClast)</measure>
    <time_frame>Day 1 - Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Concentration-Time Curve (AUC) from Time Zero extrapolated to infinity (AUCInf)</measure>
    <time_frame>Day 1 - Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-adalimumab antibodies (ADA) and neutralizing antibodies (Nab)</measure>
    <time_frame>Day 1 - Day 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax)</measure>
    <time_frame>Day 1- Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Concentration-Time Curve (AUC) time Zero to 2 weeks after Dosing</measure>
    <time_frame>Day 1- Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL)</measure>
    <time_frame>Day 1- Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Decay Half-Life (t1/2)</measure>
    <time_frame>Day 1- Day 43</time_frame>
    <description>Serum decay half-life is teh time for the serum concentration to decrease by one half</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06410293</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab-EU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adalimumab-US</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06410293</intervention_name>
    <description>40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>adalimumab-Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humira (adalimumab-EU)</intervention_name>
    <description>40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>adalimumab (European Union)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humira (adalimumab-US)</intervention_name>
    <description>40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.</description>
    <arm_group_label>C</arm_group_label>
    <other_name>adalimumab (United States)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female (non-childbearing potential). Healthy is defined as no
             clinically relevant abnormalities identified by a detailed medical history, full
             physical examination including blood pressure, pulse, ECG, and laboratory testing.

        Exclusion Criteria:

          -  Evidence or history of clinically significant infectious, hematological, renal,
             endocrine, pulmonary gastrointestinal, cardiovascular, hepatic psychiatric,
             neurologic, autoimmune, or allergic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5381001&amp;StudyName=Study%20Of%20PF-06410293%20And%20adalimumab%20In%20Healthy%20Subjects%20%28REFLECTIONS%20B538-01%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>February 13, 2014</last_update_submitted>
  <last_update_submitted_qc>February 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Phase 1</keyword>
  <keyword>PK</keyword>
  <keyword>adalimumab</keyword>
  <keyword>Single-dose</keyword>
  <keyword>Immunology</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Biosimilarity</keyword>
  <keyword>Similarity.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

